Galectin-1 Dysregulation Independently Predicts Disease Specific Survival in Bladder Urothelial Carcinoma

Wu, Tingfeng; Li, Chien‐Feng; Chien, Lan‐Hsiang; Shen, Kun‐Hung; Huang, Hsuan‐Ying; Su, Chin-Chuan; Liao, Alex Chien-Hwa

doi:10.1016/j.juro.2014.09.107

Cited by 25 publications

(43 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on the present data and previous studies, we propose that LGALS1 gene expression ramped up in UBUC specimens might provoke the Rac1−MEKK4−JNK signaling pathway to augment the JNK−c‐Jun−AP1−MMP9 pathway, which in turn stimulates tumor cell invasion. Our observations provide unprecedented insight into the molecular mechanism of UBUC invasiveness and metastasis.…”

Section: Discussionsupporting

confidence: 74%

“…Our previous cohort study reported that Gal‐1 overexpression is significantly linked to UBUC invasion . In addition, Gal‐1 silencing inhibited the invasive ability of T24 cells and MMP9 is closely associated with tumor metastasis .…”

Section: Resultsmentioning

confidence: 94%

“…In our previous cohort investigation, we found that there is a significant correlation between Gal‐1 overexpression and tumor stage, histological grade, vascular invasion, and lymph node metastasis. Increased Gal‐1 expression in UBUC significantly predicted disease‐specific survival at univariate and multivariate levels . The aforementioned study is the first to provide the clinical correlation between Gal‐1 expression, patient survival, and prognosis of UBUC .…”

Section: Discussionmentioning

confidence: 90%

“…Our previous documented cohort study showed that the LGALS1 gene is amplified in UBUC specimens and Gal‐1 overexpression is significantly linked to UBUC invasion. Galectin‐1 overexpression in tumor significantly predicted disease‐specific survival at the univariate and multivariate levels . However, the molecular pathway underlying UBUC carcinogenesis in which Gal‐1 participates has not been uncovered.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Role of galectin‐1 in urinary bladder urothelial carcinoma cell invasion through the JNK pathway

Shen

Chien

et al. 2016

Cancer Science

Self Cite

View full text Add to dashboard Cite

Human galectin‐1 is a member of the galectin family, proteins with conserved carbohydrate‐recognition domains that bind galactoside. Galectin‐1 is highly expressed in various tumors and participates in various oncogenic processes. However, detailed descriptions of the function of galectin‐1 in urinary bladder urothelial carcinoma have not been reported. Our previous cohort investigation showed that galectin‐1 is associated with tumor invasiveness and is a possible independent prognostic marker of urinary bladder urothelial carcinoma. The present study aimed to clarify the relevance of galectin‐1 expression level to tumor progression and invasion. In order to decipher a mechanism for the contribution of galectin‐1 to the malignant behavior of urinary bladder urothelial carcinoma, two bladder cancer cell lines (T24 and J82) were established with knockdown of galectin‐1 expression by shRNA. Bladder cancer cells with LGALS1 gene silencing showed reduced cell proliferation, lower invasive capability, and lower clonogenicity. Extensive signaling pathway studies indicated that galectin‐1 participated in bladder cancer cell invasion by mediating the activity of MMP9 through the Ras–Rac1–MEKK4–JNK–AP1 signaling pathway. Our functional analyses of galectin‐1 in urinary bladder urothelial carcinoma provided novel insights into the critical role of galectin‐1 in tumor progression and invasion. These results revealed that silencing the galectin‐1‐mediated MAPK signaling pathway presented a novel strategy for bladder cancer therapy.

show abstract

Section: Discussionsupporting

confidence: 74%

Section: Resultsmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 90%

mentioning

confidence: 99%

See 2 more Smart Citations

Role of galectin‐1 in urinary bladder urothelial carcinoma cell invasion through the JNK pathway

Shen

Chien

et al. 2016

Cancer Science

Self Cite

View full text Add to dashboard Cite

show abstract

“…Wu et al (page 1002) from Taiwan explored the clinical significance of abnormal GAL-1 gene expression in UBUC development. 2 They selected primary localized UBUCs for which transurethral resection of bladder tumor had been done, followed by radical cystectomy for T2 to T4 tumors. Pathological slides were examined for cytoplasmic GAL-1 immunoexpression and the correlation of GAL-1 dysregulation with clinicopathological factors and disease specific survival.…”

Section: Galectin-1 Dysregulation Predicts Bladder Cancer Survivalmentioning

confidence: 99%

This Month in Investigative Urology

Andersson¹

2015

Journal of Urology

View full text Add to dashboard Cite

Pooling analysis reveals that galectin‐1 is a reliable prognostic biomarker in various cancers

Huang

Zhang

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Galectin‐1 is reported to be upregulated in various human cancers. However, the relationship between galectin‐1 expression and cancer prognosis has not been systematically assessed. In this study, we searched PubMed, Web of Science, and Embase to collect all relevant studies and a meta‐analysis was performed. We found that increased galectin‐1 expression was associated with tumor size (odds ratio [OR] = 1.75; 95% confidence interval [CI]: 1.06–2.89; p = 0.029), clinical stage (OR = 3.89; 95% CI: 2.40–6.31; p < 0.001), and poorer differentiation (OR = 1.39; 95% CI: 1.14–1.69; p = 0.001), but not with age (OR = 1.07; 95% CI: 0.82–1.39; p = 0.597), sex (OR = 0.89; 95% CI: 0.74–1.07; p = 0.202), or lymph node metastasis (OR = 2.57; 95% CI: 0.98–6.78; p = 0.056). In addition, we found that high galectin‐1 expression levels were associated with poor overall survival (HR = 2.12; 95% CI: 1.71–2.64; p < 0.001). The results were further validated using The Cancer Genome Atlas data set. Moreover, high galectin‐1 expression was significantly associated with disease‐free survival (hazard ratio [HR] = 1.60; 95% CI: 1.17–2.19; p = 0.003), progression‐free survival (HR = 1.93; 95% CI: 1.65–2.25; p < 0.001), and cancer‐specific survival (HR = 1.82; 95% CI: 1.30–2.55; p < 0.001). Our meta‐analysis demonstrated that galectin‐1 might be a useful common biomarker for predicting prognosis in patients with cancer.

show abstract

Galectin-1 Dysregulation Independently Predicts Disease Specific Survival in Bladder Urothelial Carcinoma

Abstract: These results reveal that galectin-1 over expression is a possible independent factor for bladder cancer prognosis.

Cited by 25 publications

References 27 publications

Role of galectin‐1 in urinary bladder urothelial carcinoma cell invasion through the JNK pathway

Role of galectin‐1 in urinary bladder urothelial carcinoma cell invasion through the JNK pathway

This Month in Investigative Urology

Pooling analysis reveals that galectin‐1 is a reliable prognostic biomarker in various cancers

Contact Info

Product

Resources

About